Vahram Haroutunian, PhD
img_Vahram Haroutunian
PROFESSOR | Psychiatry
PROFESSOR | Neuroscience
Research Topics
Aging, Alzheimer's Disease, Gene Expressions, Myelination, Neurotransmitters, Post-Transcriptional Processing, Prefrontal Cortex, Psychiatry, RNA, Schizophrenia
Multi-Disciplinary Training Area
Neuroscience [NEU]

PhD, Kent State University

Princeton University


Selected Publications

Sex specific molecular networks and key drivers of Alzheimer’s disease. Lei Guo, Jiqing Cao, Jianwei Hou, Yonghe Li, Min Huang, Li Zhu, Larry Zhang, Yeji Lee, Mariana Lemos Duarte, Xianxiao Zhou, Minghui Wang, Chia Chen Liu, Yuka Martens, Michael Chao, Alison Goate, Guojun Bu, Vahram Haroutunian, Dongming Cai, Bin Zhang. Molecular Neurodegeneration

Using brain cell-type-specific protein interactomes to interpret neurodevelopmental genetic signals in schizophrenia. Yu Han H. Hsu, Greta Pintacuda, Ruize Liu, Eugeniu Nacu, April Kim, Kalliopi Tsafou, Natalie Petrossian, William Crotty, Jung Min Suh, Jackson Riseman, Jacqueline M. Martin, Julia C. Biagini, Daya Mena, Joshua K.T. Ching, Edyta Malolepsza, Taibo Li, Tarjinder Singh, Tian Ge, Shawn B. Egri, Benjamin Tanenbaum, Caroline R. Stanclift, Annie M. Apffel, Stephan Ripke, Benjamin M. Neale, Aiden Corvin, James T.R. Walters, Kai How Farh, Peter A. Holmans, Phil Lee, Brendan Bulik-Sullivan, David A. Collier, Hailiang Huang, Tune H. Pers, Ingrid Agartz, Esben Agerbo, Margot Albus, Madeline Alexander, Farooq Amin, Silviu A. Bacanu, Martin Begemann, Richard A. Belliveau, Guiqing Cai, Kenneth L. Davis, Elodie Drapeau, Joseph I. Friedman, Vahram Haroutunian, René S. Kahn, Abraham Reichenberg, Panos Roussos, Jeremy M. Silverman. iScience

Lower levels of cortical [<sup>3</sup>H]pirenzepine binding to postmortem tissue defines a sub-group of older people with schizophrenia with less severe cognitive deficits. Brian Dean, Vahram Haroutunian, Elizabeth Scarr. Schizophrenia Research

View All Publications

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Haroutunian during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.


  • Cold Spring Harbor Laboratory (CSHL)
  • Synaptec

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.